Appleton Partners Inc. MA Lowers Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Appleton Partners Inc. MA reduced its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 95.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,536 shares of the medical research company's stock after selling 30,655 shares during the period. Appleton Partners Inc. MA's holdings in IQVIA were worth $302,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in IQV. Capital Performance Advisors LLP acquired a new position in IQVIA during the third quarter valued at approximately $27,000. Avior Wealth Management LLC grew its holdings in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock valued at $38,000 after purchasing an additional 87 shares during the period. Synergy Asset Management LLC acquired a new position in IQVIA during the fourth quarter valued at approximately $33,000. Assetmark Inc. grew its holdings in IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock valued at $54,000 after purchasing an additional 196 shares during the period. Finally, UMB Bank n.a. grew its holdings in IQVIA by 74.4% during the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company's stock valued at $55,000 after purchasing an additional 99 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

IQV has been the subject of a number of analyst reports. StockNews.com cut shares of IQVIA from a "buy" rating to a "hold" rating in a report on Thursday, November 28th. BTIG Research cut shares of IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. Bank of America reduced their price target on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a report on Friday, December 13th. Leerink Partners reiterated an "outperform" rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Finally, Robert W. Baird reduced their price target on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a report on Tuesday, January 21st. Five analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and an average price target of $251.67.

IQVIA Price Performance

Shares of IQVIA stock traded down $3.25 during midday trading on Wednesday, hitting $197.64. 1,044,006 shares of the company traded hands, compared to its average volume of 1,411,836. The stock has a market cap of $35.87 billion, a price-to-earnings ratio of 26.35, a PEG ratio of 2.25 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.81 and a current ratio of 0.84. The firm's fifty day moving average price is $200.77 and its 200-day moving average price is $218.81. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.81 earnings per share for the current year.

Insider Activity at IQVIA

In related news, Director John G. Danhakl bought 1,275 shares of the company's stock in a transaction that occurred on Tuesday, December 3rd. The shares were bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the transaction, the director now directly owns 1,275 shares of the company's stock, valued at approximately $255,739.50. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is owned by corporate insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.